University of Queensland COVID-19 vaccine dumped – doubt in vaccines

University of Queensland COVID-19 vaccine dumped - doubt in vaccines

The Australian federal government has dumped a deal to buy tens of millions of doses of potential COVID-19 coronavirus vaccines being developed in Australia at the University of Queensland.

The decision was made after the University of Queensland and biotechnology company CSL abandoned clinical trials of their COVID-19 coronavirus vaccine candidate, due to unexpected response towards the virus.

Biotechnology company CSL said in a statement that while phase 1 trials of the vaccine v451 amongst 216 participants showed it was completely safe, it had made a mutual decision with the Australian federal government, not to progress.

The University of Queensland COVID-19 vaccine dumped due to false-positive HIV results during the clinical trial phase

The clinical trials were abandoned after some participants returned false-positive results of HIV illness that biotechnology company CSL described as unexpected result.

Follow up tests confirmed that there was no HIV virus presented and it was just a false positive reading on certain HIV tests. There is no possibility the vaccine causes infection, it said.

Prime Minister of Australia Scott Morrison told reporters on Friday morning

Our vaccine strategy had identified four vaccines that we believed based on the scientific advice had the potential to go through to the end of Stage 3 trials and be available here in Australia, he said.
At no stage, did we believed that all four of those vaccines would likely get through that process?

The Australian government had previously said they wanted to start rolling out a vaccine to the Australian community early in the new year most likely February March 2021.

We have other vaccine options beyond the University of Queensland and biotechnology company CSL project, including a vaccine being developed in the UK by Oxford University and pharmaceutical giant AstraZeneca in Sydney.

Prime minister Scott Morrison took the opportunity on Friday to announce the production and purchase of AstraZeneca vaccines would increase from 33.8 million to 53.8 million doses and an increase in Australian access to the Novavax vaccine from 40 million to 51 million doses.

Safety of Australian population is our first priority for our Government, Australia first.

Queensland Premier Annastacia Palaszczuk said she is very disappointed

with the University of Queensland and biotechnology company CSL outcome.
Who wouldn’t be millions of dollars spent on research and the final result – terminated.

But of course, there has been a number of companies across the globe that have been trialling different vaccines. I think you’ll see the Australian government will look very closely at the ones that are working to potentially roll out here in Australia, she said.

Maybe Australia will go with Covid-19 coronavirus vaccine maybe Russian Sputnik-V or Chinese SinoVac Vaccine I highly doubt.

Foreign epidemiologist said that no Western country will never go with Russian or Chinese Covid-19 vaccine option. If the western world will not be able to develop a successful Covid-19 vaccine they will wait until it will be developed in any other Western countries.
That’s how it works, we are not allowed to mention the option of Russian or Chinese vaccine, otherwise, we admit that our nation and Western World is not capable to make successful Covid-19 vaccine and without side effects.

Yesterday report from UK where people anaphylactoid reaction is alarming.

Covid-19 vaccines Pfizer UK cases

Pfizer said in a statement that it had been advised by the UK regulator of two yellow card reports that may be associated with the allergic reaction due to administration of the vaccine.
A precautionary measure, the MHRA has issued temporary guidance to the NHS while it conducts an investigation in order to fully understand each case and its causes. Pfizer and BioNTech are supporting the MHRA in the investigation, the statement said.
In the pivotal phase 3 clinical trial, this vaccine was generally well tolerated with no serious safety concerns reported by the independent Data Monitoring Committee. The trial has enrolled over 44,000 participants to date, over 42,000 of whom have received a second vaccination.

US drug giant Pfizer and German company BioNTech said there are – no serious safety concerns over the vaccine.

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

The reaction can occur within seconds or minutes of exposure to an allergen.
It typically causes more than one of the following Symptoms skin rash, nausea, vomiting, difficulty breathing and shock.
If not treated right away, usually with epinephrine, it can result in unconsciousness or death.

Before any health provider will administer the Vaccine is usual practice to ask and check patients card if you have any severe, life-threatening allergies before taking any vaccine.

The allergic reaction can happen from previous vaccines we know in 0.68% of cases a patient has an allergic reaction.

After information from the University of Queensland this morning and yesterday from the UK – Pfizer there is big doubt in the safety of the Covid-19 Vaccines from the public.

Novavax starts its pivotal Phase 3 clinical trial in the United States and Mexico by the end of November.

Data from the event-driven trial could support global authorization and approval, including in the U.S. The Company’s ongoing Phase 3 clinical trial in the UK to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373 is expected to be fully enrolled by the end of November. Depending on the overall COVID-19 attack rate, interim data in the UK trial, which is also event-driven, are expected as soon as early first quarter 2021.

NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. In preclinical trials, NVX-CoV2373 demonstrated induction of antibodies that block binding of spike protein to receptors targeted by the virus, a critical aspect for effective vaccine protection. In the Phase 1 portion of its Phase 1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera. NVX-CoV2373 is also being evaluated in a Phase 3 trial in the UK and two ongoing Phase 2 studies that began in August; a Phase 2b trial in South Africa, and a Phase 1/2 continuation in the U.S. and Australia. Novavax has secured $2 billion in funding for its global coronavirus vaccine program, including up to $399 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and almost $1.7 billion from the U.S. government. source Novavax

Prime Minister Scott Morrison says the Pfizer – BioNTech coronavirus vaccine being approved in the UK, US and Canada

it won’t be available here until Australian health officials are 100 % confident that it is absolutely safe.

The University of Queensland COVID-19 vaccine dumped due to false-positive HIV results during the clinical trial phase, doubt in vaccines from public

0 Comments Be First to Comment

Leave a Reply

Your email address will not be published.

You may have missed
Denmark suspends use of AstraZeneca COVID-19 vaccine